Abstract

Recent many studies indicated a novel dinucleotide variant in ss469415590 (TT vs. ΔG) of interferon-λ 4 (IFNL4) gene strongly associated with hepatitis C virus clearance. To evaluate the impact and clinical usefulness of IFNL4 ss469415590 genotype on predicting both spontaneous HCV clearance and response to therapy in Chinese population, we genotyped 795 chronic HCV carriers, 460 subjects with HCV natural clearance and 362 patients with pegylated interferon-α and ribavirin (PEG IFN-α/RBV) treatment. IFNL4 ss469415590 variant genotypes significantly decreased host HCV clearance, both spontaneous (dominant model: OR = 0.50, 95% CI = 0.36–0.71) and IFN-α induced (dominant model: OR = 0.32, 95% CI = 0.18–0.56). Multivariate stepwise analysis indicated that ss469415590, rs12979860, the level of baseline HCV RNA and platelet were as independent predictors for sustained virological response (SVR). But the area under the ROC curve (AUC) was only 0.58 for ss469415590, and it was elevated to 0.71 by adding rs12979860, baseline HCV RNA and platelet in the prediction model of SVR. Therefore, these findings underscore that although genetic factors of host and pathogen were commonly important during HCV clearance, ss469415590 may be also a strongly predictive marker in the Chinese population.

Highlights

  • The hepatitis C virus (HCV) prevalence was about 2.3% all over the world, with 170 million HCV-infected individuals and 29 million in China[1,2]

  • 362 chronic infection patients treated with PEG IFN-α/RBV therapy were recruited from a population of former paid-blood donors, which the viral genotype of these Chronic hepatitis C (CHC) were all genotype 1. 65.7% patients achieved sustained virological response (SVR)

  • These results indicated that patients with ss469415590 variant types may have a lower ability of HCV clearance, especially in viral genotype 1

Read more

Summary

Introduction

The hepatitis C virus (HCV) prevalence was about 2.3% all over the world, with 170 million HCV-infected individuals and 29 million in China[1,2]. To further test the association of IFNL4 ss469415590 variants with spontaneous HCV clearance and response to treatment, we genotyped IFNL4 ss469415590 and IL28B rs12979860 in 795 chronic HCV carriers, and 460 subjects with HCV natural clearance and 362 patients with PEG IFN-α/RBV treatment in Chinese Han populations.

Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call